Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC)

被引：21
|
作者：
Barroso-Sousa, Romualdo
Li, Tianyu
Reddy, Sangeetha
Emens, Leisha A.
Overmoyer, Beth
Lange, Paulina
Dilullo, Molly K.
Attaya, Victoria
Kimmel, Jeffrey
Winer, Eric P.
Mittendorf, Elizabeth A.
Tayob, Nabihah
Tolaney, Sara M.
机构：
来源：
CANCER RESEARCH | 2022年 / 82卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS21-GS2-10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS2-10
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Phase II trial evaluating the combination of eribulin (E) plus bevacizumab (BEV) as first line chemotherapy in patients with metastatic Her2-negative breast cancer (MBC): a GINECO group study
    Hardy-Bessard, A-C.
    Brocard, F.
    Leheurteur, M.
    Melis, A.
    Dauba, J.
    Lortholary, A.
    You, B.
    Guardiola, E.
    Grenier, J.
    Martin-Babau, J.
    Meunier, J.
    Follana, P.
    Savoye, A-M.
    Mercier-Blas, A.
    Marti, A.
    Despax, R.
    Barbier, N.
    Gane, N.
    Ardisson, P.
    Segura-Djezzar, C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
    Nederlof, Iris
    Isaeva, Olga I.
    de Graaf, Manon
    Gielen, Robbert C. A. M.
    Bakker, Noor A. M.
    Rolfes, Adrianne L.
    Garner, Hannah
    Boeckx, Bram
    Traets, Joleen J. H.
    Mandjes, Ingrid A. M.
    de Maaker, Michiel
    van Brussel, Thomas
    Chelushkin, Maksim
    Champanhet, Elisa
    Lopez-Yurda, Marta
    van de Vijver, Koen
    van den Berg, Jose G.
    Hofland, Ingrid
    Klioueva, Natasja
    Mann, Ritse M.
    Loo, Claudette E.
    van Duijnhoven, Frederieke H.
    Skinner, Victoria
    Luykx, Sylvia
    Kerver, Emile
    Kalashnikova, Ekaterina
    van Dongen, Marloes G. J.
    Sonke, Gabe S.
    Linn, Sabine C.
    Blank, Christian U.
    de Visser, Karin E.
    Salgado, Roberto
    Wessels, Lodewyk F. A.
    Drukker, Caroline A.
    Schumacher, Ton N.
    Horlings, Hugo M.
    Lambrechts, Diether
    Kok, Marleen
    NATURE MEDICINE, 2024, 30 (11) : 3223 - 3235
  • [23] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm).
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine M.
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten Dietrich
    Runswick, Sarah
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [24] OlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients (pts) with HER2-negative metastatic breast cancer (mBC) and a germline BRCA mutation (gBRCAm)
    Robson, Mark E.
    Im, Seock-Ah
    Senkus, Elzbieta
    Xu, Binghe
    Domchek, Susan M.
    Masuda, Norikazu
    Delaloge, Suzette
    Li, Wei
    Tung, Nadine M.
    Armstrong, Anne
    Wu, Wenting
    Goessl, Carsten Dietrich
    Runswick, Sarah
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [25] Advances in chemotherapy for HER2-negative metastatic breast cancer
    Mukai, Hirofumi
    Ito, Mayuko
    CHINESE CLINICAL ONCOLOGY, 2018, 7 (03)
  • [26] Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: results of a phase II trial (AGMT MBC-6)
    Rinnerthaler, Gabriel
    Gampenrieder, Simon Peter
    Petzer, Andreas
    Hubalek, Michael
    Petru, Edgar
    Sandholzer, Margit
    Andel, Johannes
    Balic, Marija
    Melchardt, Thomas
    Hauser-Kronberger, Cornelia
    Schmitt, Clemens A.
    Ulmer, Hanno
    Greil, Richard
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [27] Choice of primary endpoints in first-line phase III trials of HER2-negative or HER2-unknown metastatic breast cancer (MBC).
    Kuemmel, Sherko
    Mueller, Volkmar
    Lux, Michael P.
    Weyer, Geerd
    Pintoffl, Jan P.
    Jackisch, Christian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [28] Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B)
    Ozaki, Yukinori
    Tsurutani, Junji
    Mukohara, Toru
    Iwasa, Tsutomu
    Takahashi, Masato
    Tanabe, Yuko
    Kawabata, Hidetaka
    Masuda, Norikazu
    Futamura, Manabu
    Minami, Hironobu
    Matsumoto, Koji
    Yoshimura, Kenichi
    Kitano, Shigehisa
    Takano, Toshimi
    EUROPEAN JOURNAL OF CANCER, 2022, 171 : 193 - 202
  • [29] Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.
    Marme, Frederik
    Gerber, Bernd
    Schmidt, Marcus
    Moebus, Volker Jochen
    Foerster, Frank Gerhard
    Grischke, Eva-Maria
    Beckmann, Matthias W.
    Strumberg, Dirk
    Solomayer, Erich
    Klare, Peter
    Windemuth-Kieselbach, Christiane
    Schneeweiss, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
    Schuler, Martin
    Awada, Ahmad
    Harter, Philipp
    Canon, Jean Luc
    Possinger, Kurt
    Schmidt, Marcus
    De Greve, Jacques
    Neven, Patrick
    Dirix, Luc
    Jonat, Walter
    Beckmann, Matthias W.
    Schuette, Jochen
    Fasching, Peter A.
    Gottschalk, Nina
    Besse-Hammer, Tatiana
    Fleischer, Frank
    Wind, Sven
    Uttenreuther-Fischer, Martina
    Piccart, Martine
    Harbeck, Nadia
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 134 (03) : 1149 - 1159
12345